However, Trop-2 expression was not associated with stromal tumor-infiltrating lymphocytes (sTIL), event-free survival outcomes, or the rate of pathological complete response (PCR) after neoadjuvant chemotherapy (34). The gene discussed is TACSTD2; the disease is neoplasm.